Mon, Sep 30, 9:02 PM (91 days ago)
CytoDyn Inc. filed Amendment No. 1 to its Form 10-K for the fiscal year ended May 31, 2024, primarily to include previously omitted Part III information and correct an exhibit. The amendment does not alter any financial results reported in the original filing. As of November 30, 2023, the company reported a market value of $156,180,000 and 1,214,900,000 shares outstanding. The amendment outlines executive compensation changes, including the appointment of Jacob Lalezari as CEO and Mitchell Cohen as Interim CFO. The company’s executive compensation program aims to attract and retain talent, with base salaries for Lalezari and other executives set in line with industry standards. CytoDyn's financial condition remains stable, with no significant changes in operating expenses or earnings per share reported. Future outlook includes ongoing clinical trials and potential partnerships, although risks such as regulatory challenges persist. The company's governance structure emphasizes independence among board members, ensuring compliance with Nasdaq rules. Overall, the filing reflects a commitment to transparency and adherence to regulatory requirements.